

Yonne

Acctg 12028817

FAR No. 6

STATEMENT OF APPROVED BUDGET, UTILIZATION, DISBURSEMENTS AND BALANCES FOR TRUST RECEIPTS
(for Implementing Agency use only)
As of the Quarter Ending September 30, 2021

Department : State Universities and Colleges (SUCs)
Agency : University of the Philippine System
Operating Unit : University of the Philippines, Manila
Organization Code(UACS) :
Fund Cluster : 07 - Trust Receipts
Date Exported : October 12, 2021, 01:13:35 PM

Inter Agency Fund Transfer

Source Agencies and Projects	UACS CODE	Approved Budget			Utilizations					Disbursements					Balances		
		Approved Budgeted Revenue/Receipts	Adjustments (Additions, Reductions, Modifications/ Augmentations)	Adjusted Budget Revenue	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	Unutilized Budget	Unpaid Utilizations (18-19) = (17-18)	
																Due and Demandable	Not Yet Due and Demandable
1	2	3	4	5=(3+(-)4)	6	7	8	9	10=(6+7+8+9)	11	12	13	14	15=(11+12+13+14)	16=(5-10)	17	18
CHED		2,000,000.00		2,000,000.00		748,429.59	1,219,058.16		1,967,487.75		748,429.59	1,219,058.16		1,967,487.75	32,512.25		
		2,000,000.00		2,000,000.00		748,429.59	1,219,058.16		1,967,487.75		748,429.59	1,219,058.16		1,967,487.75	32,512.25		
UPM Unfolding the Genomic Diversity and Origin of Multi-Drug Resistant Mycobacterium Tuberculosis in the Philippines (14b-d)		2,000,000.00		2,000,000.00		748,429.59	1,219,058.16		1,967,487.75		748,429.59	1,219,058.16		1,967,487.75	32,512.25		
PS		761,416.84		761,416.84		728,904.59			728,904.59		728,904.59			728,904.59	32,512.25		
MOOE		1,238,583.16		1,238,583.16		19,525.00	1,219,058.16		1,238,583.16		19,525.00	1,219,058.16		1,238,583.16			
Dangerous Drugs Board		4,000,000.00		4,000,000.00		180,508.80	270,913.20		451,422.00		180,508.80	270,913.20		451,422.00	3,548,578.00		
		4,000,000.00		4,000,000.00		180,508.80	270,913.20		451,422.00		180,508.80	270,913.20		451,422.00	3,548,578.00		
UPM Development and Validation of a Placenta-Based Microfluidic POCT-Device (5-m) Used to Detect Intoxication With Selected New Psychoactive Substances and Pharmaceuticals (104)		4,000,000.00		4,000,000.00		180,508.80	270,913.20		451,422.00		180,508.80	270,913.20		451,422.00	3,548,578.00		
PS		2,052,979.20		2,052,979.20		180,508.80	270,763.20		451,272.00		180,508.80	270,763.20		451,272.00	1,601,707.20		
MOOE		1,787,020.80		1,787,020.80			150.00		150.00			150.00		150.00	1,786,870.80		
CO		160,000.00		160,000.00											160,000.00		
UPM AHPD & SRA and Life Insurance, Mesh & Accommodation of Healthworkers in Response to COVID-19 Health Emergency (103-28D)		1,421,060.00		1,421,060.00		1,012,469.09			1,012,469.09		1,012,469.09			1,012,469.09	408,590.91		
MOOE		1,421,060.00		1,421,060.00		1,012,469.09			1,012,469.09		1,012,469.09			1,012,469.09	408,590.91		
UPM Development and Implementation of Biosafety and Molecular Biology Training Courses for Lab. Personnel Working in COVID-C19 Testing Centers (103-28F)		5,308,019.96		5,308,019.96			4,376,752.97		4,376,752.97			4,376,752.97		4,376,752.97	931,266.99		
PS		4,658,300.00		4,658,300.00			4,359,700.00		4,359,700.00			4,359,700.00		4,359,700.00	298,600.00		
MOOE		534,719.96		534,719.96			17,052.97		17,052.97			17,052.97		17,052.97	517,666.99		
CO		115,000.00		115,000.00											115,000.00		
UPM Development of 5 Clinical Practice Guidelines (103-25)		700,000.00		700,000.00		104,026.67			104,026.67		104,026.67			104,026.67	595,973.33		
MOOE		700,000.00		700,000.00		104,026.67			104,026.67		104,026.67			104,026.67	595,973.33		
UPM Development of Medical Certificate on Cause of Death Instructional Design and Advocacy Initiatives to Philippine Medical Schools Curriculum (103-26A)		5,000,000.00	318,382.80	5,318,382.80		1,876,590.00	842,015.20		2,718,605.20		1,876,590.00	842,015.20		2,718,605.20	2,599,777.60		
PS		320,000.00	318,382.80	638,462.80		320,000.00	518,382.80		638,462.80		320,000.00	318,382.80		638,462.80			
MOOE		4,679,920.00		4,679,920.00		1,556,510.00	523,632.40		2,080,142.40		1,556,510.00	523,632.40		2,080,142.40	2,599,777.60		
DOH		44,825,083.83	3,501,828.20	47,326,912.03		8,677,609.18	12,735,811.54		21,413,420.72		8,677,609.18	12,735,811.54		21,413,420.72	25,913,491.31		
		44,825,083.83	3,501,828.20	47,326,912.03		8,677,609.18	12,735,811.54		21,413,420.72		8,677,609.18	12,735,811.54		21,413,420.72	25,913,491.31		
UPM Effect of Baseline Dengue Serostatus Among Tetravalent Dengue Vaccine CYD-DTV (Dengvaxia) Recipients on Subsequent Virologically Confirmed Dengue in the Philippines (103-21)		8,100,000.00		8,100,000.00		990,339.54	3,450,792.00		4,441,131.54		990,339.54	3,450,792.00		4,441,131.54	3,658,868.46		
PS		3,564,532.80		3,564,532.80		311,060.35	927,356.00		1,238,416.35		311,060.35	927,356.00		1,238,416.35	2,326,116.45		

10/20/2021

Source Agencies and Projects	UACS CODE	Approved Budget			Utilizations					Disbursements					Balances		
		Approved Budgeted Revenue/Receipts	Adjustments (Additions, Reductions, Modifications/ Augmentations)	Adjusted Budget Revenue	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	Unutilized Budget	Unpaid Utilizations (10-19) = (17-18)	
																Due and Demandable	Not Yet Due and Demandable
1	2	3	4	5=(3+4)	6	7	8	9	10=(6+7+8+9)	11	12	13	14	15=(11+12+13+14)	16=(5-10)	17	18
MOOE		581,737.60		581,737.60			50.00		50.00			50.00		50.00		581,687.60	
CO		50,000.00		50,000.00													50,000.00
LPM Biochemical and Immunologic Characterization and Cross-reactivity Studies of Allergenic Local Pollen Extracts (105-70)		3,789,392.58		3,789,392.58			802,746.55		802,746.55			802,746.55		802,746.55		2,986,646.03	
PS		491,771.20		491,771.20			431,496.95		431,496.95			431,496.95		431,496.95		60,274.25	
MOOE		3,807,621.38		3,807,621.38			371,349.60		371,349.60			371,349.60		371,349.60		2,436,271.78	
CO		490,000.00		490,000.00												490,000.00	
LPM Development of a Cell-Based Immunoassay for Coronavirus Disease 2019 (COVID-19) Serologic Testing (107-140)		4,994,073.84		4,994,073.84		391,452.04	397,291.20		788,744.84			391,452.04	397,291.20	788,744.84		4,205,329.80	
PS		1,182,115.20		1,182,115.20		140,419.20	397,291.20		537,710.40			140,419.20	397,291.20	537,710.40		644,404.80	
MOOE		2,414,958.64		2,414,958.64			251,033.64		251,033.64			251,033.64		251,033.64		2,163,925.00	
CO		1,397,000.00		1,397,000.00												1,397,000.00	
LPM Digital Histologic Image Analysis Software for Hirschsprung's Disease (107-45)		644,966.80		644,966.80		644,966.80			644,966.80					644,966.80			
MOOE		644,966.80		644,966.80		644,966.80			644,966.80					644,966.80			
LPM Durability and Efficacy of Protection for SARS-CoV-2 Antibodies Among Patients with COVID-19 (107-141)		10,799,884.63		10,799,884.63		1,310,944.80	3,349,857.40		4,660,802.20		1,310,944.80	3,349,857.40		4,660,802.20		6,139,082.43	
PS		4,151,341.20		4,151,341.20		1,310,794.80	1,574,367.40		2,785,062.20		1,310,794.80	1,574,367.40		2,785,062.20		1,366,279.00	
MOOE		6,396,816.45		6,396,816.45		150.00	1,675,490.00		1,675,740.00		150.00	1,675,640.00		1,675,740.00		4,721,076.45	
CO		251,726.98		251,726.98												251,726.98	
LPM Exposure of Reproductive Aged Pregnant and Non-Pregnant Women to Common Environmental Pollutants: Implications to their Reproductive Health, Pregnancy and Fetal Outcomes (107-151)		6,131,845.60		6,131,845.60		75.00	205,034.01		205,109.01		75.00	205,034.01		205,109.01		8,926,736.59	
PS		1,584,723.20		1,584,723.20			205,034.01		205,034.01			205,034.01		205,034.01		1,399,689.19	
MOOE		2,417,122.40		2,417,122.40		75.00			75.00		75.00			75.00		2,417,047.40	
CO		2,150,000.00		2,150,000.00												2,150,000.00	
LPM Formulation and Standardization of Procaine Hydrochloride - Methylprednisolone Sodium Succinate Powder for Injection (107-155)		4,664,424.20		4,664,424.20			198,946.95		198,946.95			198,946.95		198,946.95		4,465,477.25	
PS		1,237,598.40		1,237,598.40			198,871.95		198,871.95			198,871.95		198,871.95		1,038,726.45	
MOOE		1,191,825.80		1,191,825.80			75.00		75.00			75.00		75.00		1,191,750.80	
CO		2,235,000.00		2,235,000.00												2,235,000.00	
LPM Genetic, Immunological and Neurological Long-term Consequences in Prospective COVID-19 Cohort in Thailand, Japan, Philippines, and USA (107-156)		2,919,866.07		2,919,866.07			75.00		75.00			75.00		75.00		2,919,791.07	
PS		718,363.20		718,363.20								75.00		75.00		718,363.20	
MOOE		2,051,482.87		2,051,482.87			75.00		75.00							2,051,407.87	
CO		150,000.00		150,000.00												150,000.00	
LPM Intense Cell Phenotype Characterization of Moderately to Severe Coronavirus Disease 2019 (COVID-19) Patients at the Philippine General Hospital (107-125A ARCTER program, PCWRD GIA fund)		236,889.88		236,889.88			614,878.40		614,878.40			614,878.40		614,878.40		123,811.48	
PS		717,165.20		717,165.20			614,728.40		614,728.40			614,728.40		614,728.40		102,536.80	
MOOE		21,424.68		21,424.68			150.00		150.00			150.00		150.00		21,274.68	
LPM Intra-island Zoonotic Transmission of Schistosomiasis in Leyte, the Philippines (107-157)		1,052,122.02		1,052,122.02	150.00				150.00		150.00			150.00		1,051,972.02	
PS		377,287.20		377,287.20												377,287.20	
MOOE		1,274,734.82		1,274,734.82	150.00				150.00	150.00				150.00		1,274,584.82	
LPM Isolation and Characterization of Antimicrobial-Producing Microorganisms From Mangrove Soils of Alabat Island, Quezon (107-154)		9,861,748.40		9,861,748.40		150.00	185,181.60		185,331.60		150.00	185,181.60		185,331.60		9,676,416.80	
PS		1,093,454.40		1,093,454.40			185,181.60		185,181.60			185,181.60		185,181.60		908,272.80	

Source Agency and Projects	U.A.S. CODE	Approved Budget				Utilization				Disbursements				Balances				
		Approved Budgeted Receipts/Revenues	Adjustments (Additions, Reductions, Modifications/Amendments)	Adjusted Budget Revenue	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	Unutilized Budget	New Yet Due and Demandable		
1	2	3	4	5 = (3 + 4)	6	7	8	9	10 = (6 + 7 + 8 + 9)	11	12	13	14	15 = (11 + 12 + 13 + 14)	16 = (5 - 10)	17	18	
MOORE		3,318,392.00		3,318,392.00					3,318,392.00					3,318,392.00				
CO		5,450,000.00		5,450,000.00					5,450,000.00					5,450,000.00				
DOH		792,630,186.96	243,968.00	792,874,154.96	314,173.48	17,558,118.42	33,428,702.30	17,558,118.42	91,301,092.60	314,173.48	17,558,118.42	33,428,702.30	17,558,118.42	91,301,092.60	732,874,154.96			
		691,171,141.12	213,968.80	691,385,109.92	314,173.48	17,558,118.42	33,428,702.30	17,558,118.42	80,000,000.00	314,173.48	17,558,118.42	33,428,702.30	17,558,118.42	80,000,000.00	631,385,109.92			
UPM Operations Research on the Implementation of the Single Joint Rules Review Process (107-147)		428,302.65		428,302.65					428,302.65					428,302.65				
MOORE		428,302.65		428,302.65					428,302.65					428,302.65				
UPM Prescription Abuse Rates of Public Health Interventions During the CDS 10-14 Delivered (107-144)		1,361,279.06	30,648.00	1,391,927.06					1,391,927.06					1,391,927.06				
PS		881,114.80	30,648.00	911,762.80					911,762.80					911,762.80				
MOORE		510,164.26		510,164.26					510,164.26					510,164.26				
UPM Performance of a Dengue Anti-SSI Alert for the Determination of Dengue Severity Among Children in the Philippines (107-107)		6,990,000.00		6,990,000.00					6,990,000.00					6,990,000.00				
CO		8,900,000.00		8,900,000.00					8,900,000.00					8,900,000.00				
UPM Project 1: Biomarkers of Immune Dysregulation in HIV-Associated Metabolic and Neurocognitive Complications (107-130)		51,404,474.09		51,404,474.09					51,404,474.09					51,404,474.09				
PS		3,157,336.00		3,157,336.00					3,157,336.00					3,157,336.00				
MOORE		1,851,154.00		1,851,154.00					1,851,154.00					1,851,154.00				
CO		47,896,000.00		47,896,000.00					47,896,000.00					47,896,000.00				
UPM Project 1: LPHK: Design and Evaluation of External Tissue (107-132)		16,212,440.48		16,212,440.48					16,212,440.48					16,212,440.48				
PS		1,235,331.00		1,235,331.00					1,235,331.00					1,235,331.00				
MOORE		1,494,928.48		1,494,928.48					1,494,928.48					1,494,928.48				
CO		4,482,000.00		4,482,000.00					4,482,000.00					4,482,000.00				
UPM Project 1: Creation of Unique (Rugby) Addiction to Adherence Using a Randomized to Test Novel Pharmacological and Behavioral Interventions for Overcoming Withdrawal and Craving (107-130)		38,467,982.18		38,467,982.18					38,467,982.18					38,467,982.18				
PS		2,683,814.40		2,683,814.40					2,683,814.40					2,683,814.40				
MOORE		15,667,053.48		15,667,053.48					15,667,053.48					15,667,053.48				
CO		10,116,114.30		10,116,114.30					10,116,114.30					10,116,114.30				
UPM Project 1: Developing Immunity Technology System (in US) for the Management of Patients with Immune and Behavioral and Psychological Implications (107-146)		7,696,643.05		7,696,643.05					7,696,643.05					7,696,643.05				
PS		3,318,748.00		3,318,748.00					3,318,748.00					3,318,748.00				
MOORE		1,590,898.05		1,590,898.05					1,590,898.05					1,590,898.05				
CO		2,877,000.00		2,877,000.00					2,877,000.00					2,877,000.00				
UPM Project 1: Next Generation Sequencing-based System for the Identification of Novel Biomarkers and Predictors of Response to Neoadjuvant Therapy for Locoregionally-advanced Breast Cancer in Filipinos (107-139)		21,371,750.00		21,371,750.00					21,371,750.00					21,371,750.00				
PS		1,642,457.40		1,642,457.40					1,642,457.40					1,642,457.40				
MOORE		17,729,292.60		17,729,292.60					17,729,292.60					17,729,292.60				
CO		1,440,000.00		1,440,000.00					1,440,000.00					1,440,000.00				
UPM Project 2: OR-RTTAS: Operative Room Program for the Identification of Novel Biomarkers and Predictors of Response to Neoadjuvant Therapy for Locoregionally-advanced Breast Cancer in Filipinos (107-133)		10,906,614.32		10,906,614.32					10,906,614.32					10,906,614.32				
PS		2,589,838.88		2,589,838.88					2,589,838.88					2,589,838.88				
MOORE		3,247,875.92		3,247,875.92					3,247,875.92					3,247,875.92				
CO		5,171,100.00		5,171,100.00					5,171,100.00					5,171,100.00				

Source Activities and Projects	UACS CODE	Approved Budget				Expenditures				Balances							
		Approved Budgeted Revenue Receipts	Adjustments (Additions, Reductions, Modifications, Appropriations)	Adjusted Budget Revenue	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	Unutilized Budget	Due and Demandable	Not Yet Due and Demandable
1	2	3	4	5=3+4	6	7	8	9	10=6+7+8+9	11	12	13	14	15=11+12+13+14	16=15-17	17	18
LPM Project 2: Development of a Safe 1 unit Acid Bacteria (Lab-Base Bifidobacterium) Promoting Food as an Adjunct Intervention for the Management of HIV-Associated Nonbacterial Complications (107-130)		13,137,226.68		13,137,226.68	150.00		692,162.80		1,396,401.11	150.00	603,908.11	692,162.80		1,396,401.11	11,940,726.67		
PS				2,306,044.00			692,162.80		1,396,401.11		603,908.11	692,162.80		1,396,401.11	1,000,000.00		
MORE		2,306,044.00		2,306,044.00	150.00				1,396,401.11	150.00				1,396,401.11	1,000,000.00		
CU		1,578,181.88		1,578,181.88	150.00				1,396,401.11	150.00				1,396,401.11	1,000,000.00		
LPM Project 3: Lab-based A Compact Device for Measuring Intracranial Blood Flow in Head Injured Patients (107-134)		5,317,768.75		5,317,768.75	150.00		914,353.40		6,076,321.20	150.00	173,118.00	914,353.40		6,076,321.20	443,015.55		
PS		1,971,982.20		1,971,982.20			914,353.40		6,076,321.20		173,118.00	914,353.40		6,076,321.20	1,000,000.00		
MORE		1,497,811.55		1,497,811.55	150.00				6,076,321.20	150.00				6,076,321.20	1,000,000.00		
CU		1,848,975.00		1,848,975.00	150.00				6,076,321.20	150.00				6,076,321.20	1,000,000.00		
LPM Project 4: Surfactant Production and Biotransformation of Surfactant for the Management of Neonatal Respiratory Distress Syndrome (107-135)		4,096,723.51		4,096,723.51	150.00		931,319.00		5,028,042.51	150.00		931,319.00		5,028,042.51	3,165,723.51		
PS		2,580,281.60		2,580,281.60			931,319.00		5,028,042.51			931,319.00		5,028,042.51	1,000,000.00		
MORE		1,476,441.91		1,476,441.91	150.00				5,028,042.51	150.00				5,028,042.51	1,000,000.00		
CU		4,096,723.51		4,096,723.51	150.00				5,028,042.51	150.00				5,028,042.51	1,000,000.00		
LPM Project 5: Surfactant Production and Biotransformation of Surfactant for the Management of Neonatal Respiratory Distress Syndrome (107-137)		4,096,723.51		4,096,723.51	150.00		931,319.00		5,028,042.51	150.00		931,319.00		5,028,042.51	3,165,723.51		
PS		2,580,281.60		2,580,281.60			931,319.00		5,028,042.51			931,319.00		5,028,042.51	1,000,000.00		
MORE		1,476,441.91		1,476,441.91	150.00				5,028,042.51	150.00				5,028,042.51	1,000,000.00		
CU		4,096,723.51		4,096,723.51	150.00				5,028,042.51	150.00				5,028,042.51	1,000,000.00		
LPM Project 6: Surfactant Production and Biotransformation of Surfactant for the Management of Neonatal Respiratory Distress Syndrome (107-138)		4,096,723.51		4,096,723.51	150.00		931,319.00		5,028,042.51	150.00		931,319.00		5,028,042.51	3,165,723.51		
PS		2,580,281.60		2,580,281.60			931,319.00		5,028,042.51			931,319.00		5,028,042.51	1,000,000.00		
MORE		1,476,441.91		1,476,441.91	150.00				5,028,042.51	150.00				5,028,042.51	1,000,000.00		
CU		4,096,723.51		4,096,723.51	150.00				5,028,042.51	150.00				5,028,042.51	1,000,000.00		
LPM Project 7: Surfactant Production and Biotransformation of Surfactant for the Management of Neonatal Respiratory Distress Syndrome (107-139)		4,096,723.51		4,096,723.51	150.00		931,319.00		5,028,042.51	150.00		931,319.00		5,028,042.51	3,165,723.51		
PS		2,580,281.60		2,580,281.60			931,319.00		5,028,042.51			931,319.00		5,028,042.51	1,000,000.00		
MORE		1,476,441.91		1,476,441.91	150.00				5,028,042.51	150.00				5,028,042.51	1,000,000.00		
CU		4,096,723.51		4,096,723.51	150.00				5,028,042.51	150.00				5,028,042.51	1,000,000.00		
LPM Project 8: Surfactant Production and Biotransformation of Surfactant for the Management of Neonatal Respiratory Distress Syndrome (107-140)		4,096,723.51		4,096,723.51	150.00		931,319.00		5,028,042.51	150.00		931,319.00		5,028,042.51	3,165,723.51		
PS		2,580,281.60		2,580,281.60			931,319.00		5,028,042.51			931,319.00		5,028,042.51	1,000,000.00		
MORE		1,476,441.91		1,476,441.91	150.00				5,028,042.51	150.00				5,028,042.51	1,000,000.00		
CU		4,096,723.51		4,096,723.51	150.00				5,028,042.51	150.00				5,028,042.51	1,000,000.00		
LPM Project 9: Surfactant Production and Biotransformation of Surfactant for the Management of Neonatal Respiratory Distress Syndrome (107-141)		4,096,723.51		4,096,723.51	150.00		931,319.00		5,028,042.51	150.00		931,319.00		5,028,042.51	3,165,723.51		
PS		2,580,281.60		2,580,281.60			931,319.00		5,028,042.51			931,319.00		5,028,042.51	1,000,000.00		
MORE		1,476,441.91		1,476,441.91	150.00				5,028,042.51	150.00				5,028,042.51	1,000,000.00		
CU		4,096,723.51		4,096,723.51	150.00				5,028,042.51	150.00				5,028,042.51	1,000,000.00		
LPM Project 10: Surfactant Production and Biotransformation of Surfactant for the Management of Neonatal Respiratory Distress Syndrome (107-142)		4,096,723.51		4,096,723.51	150.00		931,319.00		5,028,042.51	150.00		931,319.00		5,028,042.51	3,165,723.51		
PS		2,580,281.60		2,580,281.60			931,319.00		5,028,042.51			931,319.00		5,028,042.51	1,000,000.00		
MORE		1,476,441.91		1,476,441.91	150.00				5,028,042.51	150.00				5,028,042.51	1,000,000.00		
CU		4,096,723.51		4,096,723.51	150.00				5,028,042.51	150.00				5,028,042.51	1,000,000.00		
LPM Project 11: Surfactant Production and Biotransformation of Surfactant for the Management of Neonatal Respiratory Distress Syndrome (107-143)		4,096,723.51		4,096,723.51	150.00		931,319.00		5,028,042.51	150.00		931,319.00		5,028,042.51	3,165,723.51		
PS		2,580,281.60		2,580,281.60			931,319.00		5,028,042.51			931,319.00		5,028,042.51	1,000,000.00		
MORE		1,476,441.91		1,476,441.91	150.00				5,028,042.51	150.00				5,028,042.51	1,000,000.00		
CU		4,096,723.51		4,096,723.51	150.00				5,028,042.51	150.00				5,028,042.51	1,000,000.00		
LPM Project 12: Surfactant Production and Biotransformation of Surfactant for the Management of Neonatal Respiratory Distress Syndrome (107-144)		4,096,723.51		4,096,723.51	150.00		931,319.00		5,028,042.51	150.00		931,319.00		5,028,042.51	3,165,723.51		
PS		2,580,281.60		2,580,281.60			931,319.00		5,028,042.51			931,319.00		5,028,042.51	1,000,000.00		
MORE		1,476,441.91		1,476,441.91	150.00				5,028,042.51	150.00				5,028,042.51	1,000,000.00		
CU		4,096,723.51		4,096,723.51	150.00				5,028,042.51	150.00				5,028,042.51	1,000,000.00		
LPM Project 13: Surfactant Production and Biotransformation of Surfactant for the Management of Neonatal Respiratory Distress Syndrome (107-145)		4,096,723.51		4,096,723.51	150.00		931,319.00		5,028,042.51	150.00		931,319.00		5,028,042.51	3,165,723.51		
PS		2,580,281.60		2,580,281.60			931,319.00		5,028,042.51			931,319.00		5,028,042.51	1,000,000.00		
MORE		1,476,441.91		1,476,441.91	150.00				5,028,042.51	150.00				5,028,042.51	1,000,000.00		
CU		4,096,723.51		4,096,723.51	150.00				5,028,042.51	150.00				5,028,042.51	1,000,000.00		
LPM Project 14: Surfactant Production and Biotransformation of Surfactant for the Management of Neonatal Respiratory Distress Syndrome (107-146)		4,096,723.51		4,096,723.51	150.00		931,319.00		5,028,042.51	150.00		931,319.00		5,028,042.51	3,165,723.51		
PS		2,580,281.60		2,580,281.60			931,319.00		5,028,042.51			931,319.00		5,028,042.51	1,000,000.00		
MORE		1,476,441.91		1,476,441.91	150.00				5,028,042.51	150.00				5,028,042.51	1,000,000.00		
CU		4,096,723.51		4,096,723.51	150.00				5,028,042.51	150.00				5,028,042.51	1,000,000.00		
LPM Project 15: Surfactant Production and Biotransformation of Surfactant for the Management of Neonatal Respiratory Distress Syndrome (107-147)		4,096,723.51		4,096,723.51	150.00		931,319.00		5,028,042.51	150.00		931,319.00		5,028,042.51	3,165,723.51		
PS		2,580,281.60		2,580,281.60			931,319.00		5,028,042.51			931,319.00		5,028,042.51	1,000,000.00		
MORE		1,476,441.91		1,476,441.91	150.00				5,028,042.51	150.00				5,028,042.51	1,000,000.00		
CU		4,096,723.51		4,096,723.51	150.00				5,028,042.51	150.00				5,028,042.51	1,000,000.00		
LPM Project 16: Surfactant Production and Biotransformation of Surfactant for the Management of Neonatal Respiratory Distress Syndrome (107-148)		4,096,723.51		4,096,723.51	150.00		931,319.00		5,028,042.51	150.00		931,319.00		5,028,042.51	3,165,723.51		
PS		2,580,281.60		2,580,281.60			931,319.00		5,028,042.51			931,319.00		5,028,042.51	1,000,000.00		
MORE		1,476,441.91		1,476,441.91	150.00				5,028,042.51	150.00				5,028,042.51	1,000,000.00		
CU		4,096,723.51		4,096,723.51	150.00				5,028,042.51	150.00				5,028,042.51	1,000,000.00		
LPM Project 17: Surfactant Production and Biotransformation of Surfactant for the Management of Neonatal Respiratory Distress Syndrome (107-149)		4,096,723.51		4,096,723.51	150.00		931,319.00		5,028,042.51	150.00		931,319.00		5,028,042.51	3,165,723.51		
PS		2,580,281.60		2,580,281.60			931,319.00		5,028,042.51			931,319.00		5,028,042.51	1,000,000.00		
MORE		1,476,441.91		1,476,441.91	150.00				5,028,042.51	150.00				5,028,042.51	1,000,000.00		
CU		4,096,723.51		4,096,723.51	150.00				5,028,042.51	150.00				5,028,042.51	1,000,000.00		
LPM Project 18: Surfactant Production and Biotransformation of Surfactant for the Management of Neonatal Respiratory Distress Syndrome (107-150)		4,096,723.51		4,096,723.51	150.00		931,319.00		5,028,042.51	150.00		931,319.00		5,028,042.51	3,165,723.51		
PS		2,580,281.60		2,580,281.60			931,319.00		5,028,042.51			931,319.00		5,028,042.51	1,000,000.00		
MORE		1,476,441.91		1,476,441.91	150.00				5,028,042.51	150.00				5,028,042.51	1,000,000.		


Source Agencies and Projects	UACS CODE	Approved Budget			Utilizations					Disbursements					Balances		
		Approved Budgeted Revenue/Receipts	Adjustments (Additions, Reductions, Modifications/ Augmentations)	Adjusted Budget Revenue	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	Unutilized Budget	Unpaid Utilizations (16-19) = (17+18)	
																Due and Demandable	Not Yet Due and Demandable
1	2	3	4	5=(3+(-4))	6	7	8	9	10=(6+7+8+9)	11	12	13	14	15=(11+12+13+14)	16=(5-10)	17	18
		203,551.56		203,551.56											203,551.56		
UPM Validating the Performance of the National Health Insurance Program (153C)		203,551.56		203,551.56											203,551.56		
MOOE		203,551.56		203,551.56											203,551.56		
PITAHC		399,823.98		399,823.98		137,375.70			137,375.70		137,375.70			137,375.70	262,448.28		
		399,823.98		399,823.98		137,375.70			137,375.70		137,375.70			137,375.70	262,448.28		
UPM Formulation and in vivo Evaluation Studies of Syrup and Tablet Containing Alternanthera sessilis and Phyllanthus niruri aqueous Crude Extracts for Anemia and Thrombocytopenia (Phase 1) 165-16		399,823.98		399,823.98		137,375.70			137,375.70		137,375.70			137,375.70	262,448.28		
PS		267,004.00		267,004.00		30,278.40			30,278.40		30,278.40			30,278.40	236,725.60		
MOOE		132,819.98		132,819.98		107,097.30			107,097.30		107,097.30			107,097.30	25,722.68		
GRAND TOTAL		838,418,645.43	2,744,787.00	838,163,432.43	314,173.48	27,302,141.69	47,670,486.80		75,286,801.97	314,173.48	37,302,141.69	47,670,486.80		75,286,801.97	763,876,630.46		
PS		291,463,922.91	2,160,833.40	293,624,786.31	313,123.48	20,345,185.98	39,498,632.77		60,156,942.20	313,123.48	20,345,185.98	39,498,632.77		60,156,942.20	233,467,814.11		
MOOE		402,397,504.01	883,953.60	403,981,487.61	1,050.00	6,461,955.74	7,344,114.03		13,807,119.77	1,050.00	6,461,955.74	7,344,114.03		13,807,119.77	389,174,337.84		
CO		141,557,218.51		141,557,218.51		495,000.00	827,746.09		1,322,746.09		495,000.00	827,746.09		1,322,746.09	140,234,478.51		

Certified Correct:



LOVELLE C. SAGUID
Chief Budget Officer

Date:


Certified Correct:


ERWIN A. DANDO, CPA
Chief Accountant
Date:

Recommended By:


MICHAEL L. TEE, MD, MHPEd
Vice Chancellor for Planning and Development
Date:

Approved By:


CARMENCITA D. PADILLA, MD, MAHPS
Chancellor
Date: